This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Nuvilex's President And CEO In Singapore For Meetings With Its Subsidiary Austrianova Singapore

SILVER SPRING, Md. and SINGAPORE, Singapore, Aug. 24, 2012 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB: NVLX), an international biotechnology provider of cell and gene therapy solutions, announced today that Dr. Robert F. Ryan, President and CEO of Nuvilex, is in Asia and Singapore this week for numerous meetings with the Executives and staff of its wholly-owned subsidiary, Austrianova Singapore (ASPL), as well as other companies and groups in the region.

In addition to specific work with Dr. Walter Gunzburg, ASPL Chairman, and Dr. Brian Salmons, President and CEO of ASPL, and the other ASPL executives and staff regarding Nuvilex's pancreatic cancer treatment, other avenues for the development of Nuvilex and its Cell-in-a-Box® live cell encapsulation technology have been discussed.

Since his arrival Tuesday, management has been working closely together discussing possible partnerships with other entities regarding the use of the cell encapsulation technology, a major combined effort for the company. Meetings in Beijing and Singapore have included discussions with previous partners of ASPL regarding potential business opportunities.

In commenting upon his effort in Singapore, Dr. Ryan stated, "These meetings, especially those with the staff of the recently-acquired subsidiary, Austrianova Singapore, have been both timely and crucial as Nuvilex progresses in the biotechnology arena. It's important to establish and solidify the link between our two companies and staff and to ensure a seamless integration of ASPL into Nuvilex for the benefit of all of our staff and future. This is turning out to be a fantastic experience and I believe much will be gained from my visit."

About Nuvilex

Nuvilex, Inc. (OTCQB: NVLX) is an international biotechnology provider of live therapeutically valuable, encapsulated cells and services for research and medicine. A great deal of work is ongoing to move Nuvilex and our Austrianova Singapore subsidiary forward. More information is anticipated to be coming regarding Dr. Ryan's ongoing travel for the Company. Our company's clinical offerings will include cancer, diabetes and other treatments using the company's cell and gene therapy expertise and live-cell encapsulation technology. 

The Nuvilex, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13494

Safe Harbor Statement

This press release contains forward-looking statements described within the 1995 Private Securities Litigation Reform Act involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.

CONTACT: Investor Relations Contact:
         Marlin Molinaro
         Marmel Communications, LLC
         Ph: (702) 434-8692
         mmolinarofc@aol.com

Nuvilex, Inc. Logo

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,912.11 -70.48 -0.42%
S&P 500 1,969.95 -8.96 -0.45%
NASDAQ 4,442.6980 -2.2110 -0.05%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs